Data Presented at IDWeek Reports AVYCAZ Demonstrated In Vitro Antimicrobial Activity Against Common Enterobacteriaceae Pathogens

Loading...
Loading...
Researchers presented data at IDWeek from the International Network for Optimal Resistance Monitoring (INFORM) program, one of the largest ongoing surveillance programs in the United States. This program is part of a research effort developed and supported by Allergan plc
AGN
that monitors the prevalence of resistant bacteria and changing trends of resistance, as well as the in vitro activity of antibiotics against these pathogens. "The INFORM program represents Allergan's significant commitment to investing in research that advances our understanding of the prevalence, impact and appropriate management of infections caused by resistant Gram-negative pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE)," said David Melnick, M.D., Vice President, Clinical Development, Anti-Infectives, Allergan.   Carbapenem-resistant Enterobacteriaceae (CRE) is one of the three most urgent public health threats identified by the U.S. Centers for Disease Control and Prevention (CDC).1 Klebsiella pneumoniae carbapenemase (KPC) producing bacteria are a common subset of CRE bacteria and account for approximately 85 percent of all CRE infections in the U.S.1 The INFORM data presented at IDWeek reported that the antibiotic AVYCAZ™ (ceftazidime and avibactam) demonstrated potent in vitro
See full press release
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...